Drug intelligence / Profile preview

quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous, Rectal, Subcutaneous
01

Overview

This is a combination of eight psychiatric medications: - **Quetiapine and Olanzapine**: Atypical antipsychotics that work by antagonizing multiple neurotransmitter receptors, including serotonin 5-HT2A and dopamine D2 receptors. - **Mirtazapine**: An atypical antidepressant that enhances noradrenergic and serotonergic neurotransmission through antagonism of central α2-adrenergic autoreceptors. - **Carbamazepine**: An anticonvulsant and mood stabilizer that works by blocking sodium channels. - **Sertraline**: A selective serotonin reuptake inhibitor (SSRI) antidepressant. - **Amitriptyline**: A tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine. - **Chlorpromazine**: A first-generation (typical) antipsychotic that blocks dopamine D2 receptors. - **Risperidone**: An atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. This specific combination is not a standard treatment regimen and would represent polypharmacy with significant risk of drug interactions and additive side effects, including anticholinergic effects, sedation, metabolic effects, and cardiac risks.

02

Targets

SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)NaV (Voltage-gated sodium channels)HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)ADRA2A (α2A)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call